Abstract
Triglycerides represent 1 component of a heterogeneous pool of triglyceride-rich lipoproteins (TGRLs). The reliance on triglycerides or TGRLs as cardiovascular disease (CVD) risk biomarkers prompted investigations into therapies that lower plasma triglycerides as a means to reduce CVD events. Genetic studies identified TGRL components and pathways involved in their synthesis and metabolism. We advocate that only a subset of genetic mechanisms regulating TGRLs contribute to the risk of CVD events. This "omic" approach recently resulted in new targets for reducing CVD events.
Original language | English |
---|---|
Pages (from-to) | 2525-2540 |
Number of pages | 16 |
Journal | Journal of the American College of Cardiology |
Volume | 64 |
Issue number | 23 |
DOIs | |
State | Published - 2014 |
Keywords
- Atherosclerosis
- Cardiovascular disease
- Genetics
- Triglyceride
- Triglyceride-rich lipoproteins